22 Jan 2019 07:00
For immediate release 22 January 2019
Evgen Pharma plc
("Evgen" or "the Company")
Change of Adviser
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the appointment of finnCap Ltd as Nominated Adviser and Joint Broker to the Company with immediate effect.
Barry Clare, Chairman of Evgen Pharma, said:
"We are very excited to be working with finnCap and WG Partners in this important year for Evgen. We would like to thank Northland Capital for their support and contribution since our IPO in 2015.''
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com
| c/o +44 (0) 20 7466 5000 |
finnCapp Geoff Nash, Teddy Whiley (Corporate Finance) Alice Lane, Manasa Patil (ECM) www.finncap.com
| +44 (0) 20 7220 0500 |
WG Partners LLP Nigel Barnes, Claes Spång
| +44 (0) 20 3705 9330 |
Buchanan Mark Court, Sophie Wills, Tilly Abraham evgen@buchanan.uk.com
| +44 (0) 20 7466 5000 |
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com